2023-10-30T11:30:21-05:00 2022-12-31 910189318 MOSS ADAMS LLP 4747 EXECUTIVE DR SUITE 1300 SAN DIEGO CA 92121 990 2022-01-01 521842938 J CRAIG VENTER INSTITUTE JCRA 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 JOHN CRAIG VENTER CHAIRMAN AND CEO 8582001800 2023-10-23 1 JOHN CRAIG VENTER 999009999 1 PATRICIA J MAYER P00188643 8586271400 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z JOHN CRAIG VENTER 4120 CAPRICORN LANE LA JOLLA CA 92037 52050921 0 X WWW.JCVI.ORG X 1993 MD JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MORE ABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERS ABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL. 7 5 143 7 27731 15119 24288254 16500408 125747 0 1027985 -15395627 5940 27731 25447926 1132512 2966984 2934839 0 0 16793365 14376767 0 0 609335 8903709 6002601 28664058 23314207 -3216132 -22181695 93744354 56307767 32534912 9402615 61209442 46905152 X J. CRAIG VENTER INSTITUTE (JCVI) IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION ADVANCING THE SCIENCE OF GENOMICS COMMITTED TO ACCELERATING FOUNDATIONAL SCIENTIFIC RESEARCH TO DRIVE ADVANCES IN HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY. THIS PAST YEAR JCVI COMMITTED RESEARCH EFFORTS IN HUMAN HEALTH (WITH SPECIAL FOCUS ON THE SARS-COV-2 VIRUS) ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, AND SOFTWARE TOOLS AND TECHNOLOGY. 2022 HIGHLIGHTS AND UPDATES ARE AS FOLLOWS: 0 0 7241059 2890979 0 DEPARTMENT OF HEALTH AND HUMAN SERVICES: TWO MILLION PEOPLE IN THE U.S. ARE DIAGNOSED ANNUALLY WITH LIFE-THREATENING INFECTIONS CAUSED BY ANTIBIOTIC RESISTANT BACTERIA THAT ARE RESPONSIBLE FOR 35,000 DEATHS EACH YEAR WITH AN ECONOMIC IMPACT ESTIMATED TO BE AS MUCH AS $20 BILLION A YEAR IN DIRECT HEALTHCARE COSTS. DUE TO THE SPREAD OF ANTIBIOTIC RESISTANCE, VERY FEW DRUGS REMAIN THAT CAN TREAT THESE INFECTIONS. LED BY DERRICK FOUTS, PHD, (JCVI) AND FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE J. CRAIG VENTER INSTITUTE AND CLEVELAND VA PREVENTION AND INTERVENTION EPICENTER ARE DEVELOPING NOVEL INTERVENTIONS THAT WILL PREVENT THE COLONIZATION AND SPREAD OF ANTIBIOTIC RESISTANT (AR) BACTERIA THAT CAUSE HOSPITAL ACQUIRED INFECTIONS (HAI), AND TO DEVELOP DIAGNOSTICS AND INTERVENTIONS TO COMBAT THE COLONIZATION BY THE RAPIDLY EMERGING FUNGAL PATHOGEN CANDIDA AURIS. RICHARD SCHEUERMANN, PHD, IS LEADING A TEAM OF INVESTIGATORS AT JCVI IN RESPONSE TO THE COVID-19 OUTBREAK. THROUGH HIS NIH-SPONSORED BIOINFORMATICS RESOURCE CENTER PROJECT, HIS TEAM RELEASED A DEDICATED PUBLIC WEB PORTAL FOR THE SARS-COV-2 VIRUS DURING THE EARLY STAGES OF THE OUTBREAK TO ENSURE DATA AND TOOLS ARE ACCESSIBLE TO FRONTLINE RESEARCHERS WORLDWIDE. ADDITIONALLY, IN COLLABORATION WITH INVESTIGATORS FROM LA JOLLA INSTITUTE FOR IMMUNOLOGY, DR. SCHEUERMANN AND HIS TEAM PROVIDED MACHINE LEARNING METHODS TO HELP COMPLETE THE FIRST ANALYSIS THAT IDENTIFIED POTENTIAL TARGETS FOR HUMAN IMMUNE RESPONSES TO SARS-COV-2 INFECTION. THIS INFORMATION IS CRUCIAL TO THE DESIGN AND EVALUATION OF DIAGNOSTICS AND VACCINE CANDIDATES. 2957902 43860 0 DEPARTMENT OF ENERGY: JCVI IS THE RECIPIENT OF A LARGE COLLABORATIVE ASSISTANCE AWARD FROM THE US DEPARTMENT OF ENERGY. AWARDED TO THE VALUE OF $10.7M. LED BY ANDREW ALLEN, PHD, THE JCVI AND ITS COLLABORATORS, COLORADO STATE UNIVERSITY, VANDERBILT UNIVERSITY AND THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, SEEK TO LEVERAGE SIGNIFICANT RECENT ADVANCES IN DIATOM GENOME ENGINEERING AND METABOLIC MODELING; INCLUDING THE ABILITY TO INTRODUCE CHROMOSOME-LIKE EXPRESSION PLATFORMS, WHICH SUBSTANTIALLY ADVANCE POSSIBILITIES FOR HIGH-THROUGHPUT GENERATION AND SCREENING OF GENETICALLY ENGINEERED DIATOMS. RESEARCH PROPOSED HERE WILL RESULT IN DRAMATIC IMPROVEMENTS IN THE PREDICATIVE CAPACITY OF EXISTING GENOME SCALE METABOLIC MODELS OF DIATOM METABOLISM. FOR THE FIRST TIME ON A LARGE SCALE, FLUXOMICS, WHICH IS COMPOUND SPECIFIC INCORPORATION OF AN ISOTOPICALLY-LABELED FEEDSTOCK, WILL BE USED TO PROVIDE BETTER FIRST STEP CONSTRAINTS ON CO2 ASSIMILATION OF IN DIATOMS. STATE-OF-THE-ART HIGH THROUGHPUT IN VITRO EXAMINATIONS OF NEARLY ALL 200 DIATOM TRANSCRIPTION FACTORS WILL BE CONDUCTED TO BETTER UNDERSTAND REGULATORY ARCHITECTURE UNDERLYING DIATOM METABOLISM AS WELL AS SERVE AS A SOURCE FOR NEW TOOLS FOR GENOME ENGINEERING. TAKEN TOGETHER, RESEARCH PROPOSED HERE WILL ADDRESS CURRENTLY LIMITING BOTTLENECKS THROUGH FOSTERING STATE-OF-THE-ART INTEGRATION OF GENOME-SCALE MODELING WITH GENOME ENGINEERING TO OPTIMIZE ENERGY AND METABOLTE FLUX THROUGH SUBCELLULAR COMPARTMENTS TO PROMOTE EFFICIENT PRODUCTION OF HIGH VALUE AND FUEL-RELATED METABOLITES. 1020674 0 0 DEPARTMENT OF DEFENSE: WOUND MICROBIOME PROJECT - CHRONIC WOUNDS ARE WOUNDS THAT FAIL TO HEAL AFTER 3 MONTHS UNDER STANDARD OF CARE WOUND MANAGEMENT. DERRICK FOUDS LEADS A STUDY TO GAIN A BETTER UNDERSTANDING OF THE DIFFERENT CLASSES OF MICROBES THAT COULD BE PRESENT IN HUMAN CHRONIC WOUNDS (I.E. THE WOUND MICROBIOME), AND ASK WHETHER SPECIFIC MICROBES OR MICROBIAL COMMUNITIES ARE ASSOCIATED WITH NON-HEALING WOUNDS. LED BY DERRICK FOUTS, PHD, NEXT GENERATION SEQUENCING IS BEING USED TO IDENTIFY AND CATALOG THE MICROBIAL SPECIES OF BACTERIA, FUNGI, AND VIRUSES THAT ARE PRESENT IN CHRONIC WOUND SPECIMENS. COMPUTATIONAL AND BIOINFORMATICS ANALYSES OF THE MICROBIAL COMMUNITY DNA SEQUENCES WILL BE CARRIED OUT TO CHARACTERIZE THE PRESENCE ANY PATHOGENIC, VIRULENCE, AND ANTIMICROBIAL RESISTANCE-RELATED GENES AND PATHWAYS. THE EVENTUAL GOAL IS TO IDENTIFY ANY PATHOGENIC SPECIES OR FEATURES THAT ARE ASSOCIATED WITH NON-HEALING WOUNDS, AND COULD BE USED AS DIAGNOSTIC AND TREATMENT TARGETS OF CHRONIC WOUNDS. THROUGH AN IARPA-FUNDED COLLABORATION WITH INVESTIGATORS AT HARVARD WYSS INSTITUTE, JOHN GLASS, PHD, IS USING IN VITRO CELL CULTURE SYSTEMS TO ASSESS THE CAPACITY OF SARS-COV-2 PROTEINS TO INHIBIT ANTIVIRAL MECHANISMS OF THE HUMAN INNATE IMMUNE SYSTEM THAT WOULD OTHERWISE PREVENT VIRAL REPLICATION IN THOSE CELLS. 1839025 0 0 OTHER: AS PART OF THEIR INAUGURAL GRANT CYCLE, THE CONRAD PREBYS FOUNDATION FUNDED THE INSTITUTES RESEARCH WORK IN BOTH CORONARY ARTERY DISEASE AND SARS-COV-2. HEART DISEASE IS THE LEADING CAUSE OF DEATH IN THE US AND CORONARY ARTERY DISEASE (CAD) IS THE MOST COMMON TYPE OF HEART DISEASE, KILLING ~366,000 PEOPLE ANNUALLY IN THE US. ABOUT 6.7% (18.2 MILLION) US ADULTS HAVE CAD AND ~20% OF DEATHS FROM CAD OCCUR BEFORE AGE 65. A LIST OF GENETIC FACTORS LINKED TO CAD HAS BEEN FOUND OVER THE LAST FEW DECADES. BUT THEY ONLY EXPLAIN A SMALL PORTION OF THE HERITABILITY IN CAD. TO BETTER UNDERSTAND THE GENETICS AND ETIOLOGY OF CAD AT GENOMIC LEVEL, MORE RARE GENETIC VARIANTS NEED TO BE INVESTIGATED. LED BY WEIZHONG LI, THIS PROJECT, ANALYZED THE WHOLE GENOME DEEP SEQUENCE DATA OF A LARGE COHORT OF ~1000 CAD PATIENTS. USING THE CLOUD-BASED GENOME ANALYSIS PIPELINE, HUNDREDS OF TERABYTES OF SEQUENCE DATA WERE PROCESSED AND MILLIONS OF VARIOUS TYPES OF GENETIC VARIANTS WERE IDENTIFIED. A LIST OF VARIANTS ARE FOUND TO BE ASSOCIATED WITH CAD AND THE EXTENT OF DISEASE IN CAD. BY USING MACHINE LEARNING APPROACHES, WE BUILT VERY ACCURATE PREDICTIVE MODELS FOR THE PREDICTION OF CAD RISKS AND DISEASE SEVERITY. EARLY WARNING SYSTEM FOR SARS-COV-2 IMMUNE ESCAPE PROJECT. NEUTRALIZING ANTIBODIES ELICITED AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) SPIKE PROTEIN IS WIDELY ACCEPTED AS THE MAIN CORRELATE OF PROTECTION. TO BETTER UNDERSTAND THE ROLE OF ANTIBODIES IN NEUTRALIZATION AND PROTECTION, JCVI, LED BY RICHARD SCHEUERMANN, PHD, AND GENE TAN, PHD, IS CONSTRUCTING A PANEL OF CHIMERIC PSEUDOVIRUSES (BASED ON THE VESICULAR STOMATITIS VIRUS PLATFORM) THAT WE HYPOTHESIZE CAN REVEAL THE IMMUNOLOGICAL DOMINANT AND SUBDOMINANT ANTIGENIC REGIONS OF THE SPIKE PROTEIN. NOTABLY, OUR APPROACH CAN IDENTIFY SUBDOMINANT REGIONS WITHIN THE SPIKE THAT ARE HIGHLY CONSERVED EVEN AMONGST SARS-COV-2 VARIANTS OF CONCERN (VOCS). COVID19 CONTINUES TO IMPACT GLOBAL HEALTH, HIGHLIGHTING THE NEED TO DEVELOP NOVEL THERAPEUTICS. MARCELO FREIRE, PHD, AND HIS LABORATORY DISCOVERED THAT SALIVA IS A BIOFLUID IMPORTANT FOR MEASURING THE VIRUS BUT ALSO THE IMMUNE RESPONSE PRESENTING DIVERSE IMMUNE CELL POPULATIONS. WHITIN SALIVA, WE FIND VARIOUS ANTIVIRAL, ANTI-INFLAMMATORY AND ANTI-BACTERIAL FUNCTIONS. DIFFERENT FROM BLOOD, SALIVARY IMMUNE CELLS ARE IN DIRECT CONTACT WITH THE LIVE VIRUS. IN THIS PROPOSAL WE INVESTIGATED (I) THE COMPOSITION OF ANTIVIRAL IMMUNE CELLS, (II) THE PROTEIN SEQUENCE OF ANTIVIRAL MOLECULES DERIVED FROM INNATE IMMUNE CELLS, AND (III) THEIR MECHANISM OF ACTION. THE FREIRE LAB HAVE SUCCESSFULLY COLLECTED SAMPLES FROM COVID-19 AND HEALTHY CONTROL SAMPLES AND INITIATED SEQUENCING OF SALIVA CELLS IN HEALTH AND IN COVID-19. IN ADDITION, WE ALSO RECRUITED SAMPLES LONGITUDINALLY AT JCVI TO EVALUATE HEALTHY VERSUS DISEASE. TO DATE, WE COMPLETED IMMUNOGLOBULIN IMMUNOASSAYS OF ALL OUR SAMPLES INCLUDING INVESTIGATIONS TO CUSTOM ELISA ASSAYS FOR SARS-COV-2 ANTIGENS (RBD, S1, S2, NP PROTEINS). WE HAVE IDENTIFIED THAT SALIVARY IMMUNOGLOBULIN IGA AS HIGHLY SIGNIFICANT COMPARED TO BLOOD PLASMA LEVELS. SEVERAL MARKERS FROM IGG AND IGA RESPONSES WERE FOUND IN SALIVA AS WELL AS PLASMA. SIMPLE LINEAR REGRESSION MODEL VERIFIED SIGNIFICANT CORRELATIONS BETWEEN SALIVA AND PLASMA ANTIBODY RESPONSES, SPECIFICALLY FOR THE IGA (P=0.001), IGG (P=0.037), AND IGM (P=0.0054) SPECIFIC TO THE SARS-COV-2 RECEPTOR BINDING SITE (RBD). THESE ARE ANTIVIRAL MOLECULES THAT HAVE POTENTIAL TO BLOCK VIRAL ACTIVITY. TO TEST THIS FURTHER FROM OUR ASSAYS, JCVI PERFORMED A NEUTRALIZATION ASSAY AND COMPARATIVE ANALYSIS TO UNDERSTAND IF THESE MOLECULES HAVE A FUNCTIONAL RESPONSE. DESPITE THAT SALIVA CONTAINED ROBUST IGA RESPONSE TO THE SARS-COV-2, WHICH WAS EVEN HIGHER THAN PLASMA, MOST OF SALIVA SAMPLES DEMONSTRATED LEVEL OF NEUTRALIZATION OF VESICULAR STOMATITIS VIRUS (VSV) PSEUDOVIRUSES BEARING S OF SARS-COV-2 (RVSV-GFPG*SPIKE). IT WAS CONTRASTED WITH THAT THE PLASMA DISPLAYED A SIGNIFICANT LEVEL OF NEUTRALIZING ACTIVITY EVEN FROM HEALTHY INDIVIDUALS. THESE RESULTS SUGGEST THAT THE ORAL MUCOSAL IMMUNE COMPONENTS COOPERATE WITH SYSTEMIC IMMUNE RESPONSE IN RESPONSE TO THE SARS-COV-2 INFECTION. SALIVA AND PLASMA SAMPLES CONTAINED SIGNIFICANTLY HIGHER LEVELS OF SARS-COV-2 SPECIFIC ANTIBODIES THAN HEALTHY AND WE DISCOVERED MULTIPLE PEPTIDES PRESENT A ROLE AGAINST VIRAL PARTICLES. ULTIMATELY, THIS PROJECT AIMS TO MAP THE SALIVARY MOLECULAR CONTENT WHEN EXPOSED TO THE VIRUS. WE AIM PROVIDE TO THE SCIENTIFIC COMMUNITY A NEW LAYER OF IMMUNE RESPONSE COMPOSITION AND FUNCTION RELATED TO MUCOSAL LINING WHEN FACING VIRAL ATTACK. THIS WILL THEN GUIDE NEW CLINICAL APPROACHES WITH THE FORMATION OF THE THERAPEUTICS THAT EMULATE HOW AND WHY THE MUCOSAL TISSUES KEEP DISEASE IN CHECK. SANJAY VASHEE, PHD, COLLABORATING WITH INVESTIGATORS AT THE UNIVERSITY OF MARYLAND TO USE SYNTHETIC GENOMICS TO DEVELOP A SARS-COV-2 INFECTIOUS CLONE. THEY ARE PAIRING THIS WITH A RAPID, MODULAR REVERSE GENETIC SYSTEM TO ASSESS GENOMIC VARIANTS IDENTIFIED IN THE WEALTH OF GLOBAL SEQUENCING DATA, DEVELOP AND TEST VACCINE CANDIDATES, AND GENERATE NEEDED REAGENTS, INCLUDING FLUORESCENT AND TAGGED VIRUS STRAINS. MARCELO FREIRE, PHD, IS LEADING EFFORTS IN THE DEVELOPMENT OF A SALIVARY SEROLOGICAL AND IMMUNE TESTING. MONITORING SALIVA IMMUNITY PROVIDES NON-INVASIVE MOLECULAR INFORMATION, ESSENTIAL FOR DIAGNOSTICS, AND RESPONSE TO THERAPY DURING THE PANDEMIC. HIS LABORATORY IS COMPARING COVID-19 PATIENTS' BLOOD AND SALIVARY IMMUNOGLOBULINS LEVELS TO FIND BETTER WAYS TO EVALUATE IMMUNE RESPONSE TO SARS-COV-2. 1839025 0 0 13058660 1 1 0 0 0 0 0 1 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 39 0 1 143 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 7 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA IL MD X DR JOHN CRAIG VENTER 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 VENTER JOHN CRAIG CHAIRMAN & CEO 40.00 X X 1191065 0 17720 SCHEUERMANN RICHARD H DIRECTOR, LA JOLLA CAMPUS 40.00 X 355800 0 28436 KOWALSKI HEATHER CHIEF OPERATING OFFICER 40.00 X X 360452 0 18533 MULLEN JILL SR. VP OF PHILANTHROPY 40.00 X 309153 0 29556 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 40.00 X 294619 0 15442 YUMUL MARY VP OF HUMAN RESOURCES 40.00 X 254449 0 32139 STOUT MARTIN CHIEF TECHNOLOGY OFFICER 40.00 X 257144 0 28662 STAYEAS TIMOTHY NETWORK TEAM LEAD 40.00 X 216323 0 28877 FOUTS DERRICK PROFESSOR 40.00 X 201750 0 30448 SINGH INDRESH SR. SOFTWARE ENGINEER 40.00 X 200678 0 28184 ADELSON JULIE VP, LEG. AFFRS/GENERAL COUNSEL 20.00 X 197221 0 9233 BADR-EL-DIN AMIN PHD TRUSTEE 1.00 X 0 0 0 MCGRORY JACK TRUSTEE (THRU 08/22) 2.00 X 0 0 0 NORRBY ERLING TRUSTEE 1.00 X 0 0 0 RUGGLES RUDY TRUSTEE 1.00 X 0 0 0 WEI WU TRUSTEE 1.00 X 0 0 0 WOLF RICHMOND TRUSTEE 1.00 X 0 0 0 3838654 0 267230 35 0 1 0 TB CONSULTING 8328 E HARTFORD DRIVE SUITE 102 SCOTTSDALE AZ 85255 COMPUTER SERVICE CONSULTANT 240656 GIBSON DUNN & CRUTCHER LLP 333 SOUTH GRAND AVENUE LOS ANGELES CA 90071 LEGAL FEES 199379 MOSS ADAMS LLP 4747 EXECUTIVE DRIVE SUITE 1300 SAN DIEGO CA 92121 ACCOUNTING AND AUDIT SERVICES 151968 3 14857559 1642849 16500408 726080 726080 9796702 25000000 9364279 41554130 432423 -16554130 -16121707 -16121707 K-1 PASSTHROUGH 900001 27731 27731 27731 1132512 0 27731 -15395627 2890979 2890979 43860 43860 2774325 384236 2390089 9352832 5709724 3190311 452797 355411 178596 163545 13270 1130364 568014 520145 42205 763835 383831 351484 28520 228878 228878 288053 288053 95800 95800 300059 39708 260351 19015 19015 530272 175006 352635 2631 413380 11232 402148 1158313 574141 525756 58416 112270 87252 16156 8862 34969 34969 45528 29972 15000 556 558116 457953 98315 1848 420103 22176 397697 230 LAB EQUIPMENT/SUPPLIES 1797845 1467011 330834 23314207 13058660 9646212 609335 947992 5102233 2038044 395507 5217629 15575492 23013 7507 588140 311397 14864779 13006124 43348769 1858655 37716085 27086686 1125276 689927 2739406 5280363 93744354 56307767 4784511 2689803 2778999 2973249 24971402 0 0 3739563 32534912 9402615 X 60600584 34764101 608858 12141051 61209442 46905152 93744354 56307767 X -22181695 -3974864 11852269 X 0 1 X 1 1 1 X 30012027 21442951 18613419 24288254 16500408 110857059 14850000 14850000 30012027 21442951 18613419 24288254 31350408 125707059 3556219 122150840 1387304 1158537 905885 855862 726080 5033668 15119 15119 130755846 1857590 0.93420 0.91910 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2545000 X X X 0 1395244 550505 844739 13469535 12455619 1013916 1858655 OTHER ASSETS 2725900 RIGHT OF USE ASSETS 2554463 5280363 LEASE LIABILITY 3739563 3739563 X 11884117 -3974864 14850000 10875136 1008981 95800 27731 123531 1132512 26188407 2970000 2970000 23218407 95800 95800 23314207 PART III, LINE 4: COLLECTION OF SCIENTIFIC WRITINGS RELEVANT TO GENOMIC RESEARCH. PART X, LINE 2: THE INSTITUTE IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE INSTITUTE DOES NOT BELIEVE THERE ARE ANY MATERIAL UNCERTAIN TAX POSITIONS AND ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE INSTITUTE IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIOD IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: K-1 PASSTHROUGH 27,731. 1 CAYMAN ISLANDS 0 0 INVESTMENTS 144687 CENTRAL AMERICA AND THE CARIBBEAN - ANTIGUA & BARBUDA, ARUBA, BAHAMAS, 0 0 PROGRAM SERVICES RESEARCH SUBGRANTS 20942 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES RESEARCH SUBGRANTS 22919 0 0 0 0 0 0 188548 0 188548 CENTRAL AMERICA AND THE CARIBBEAN UNIVERSITY OF WEST INDIES, PROGRAM SERVICES/RESEARCH SUBGRANTS 20942 WIRE OR CHECK 0 EUROPE (INCLUDING ICELAND AND GREENLAND) UNIVERSITY OF OULU, PROGRAM SERVICES/RESEARCH SUBGRANTS 22919 WIRE OR CHECK 0 2 0 0 0 0 0 1 0 PART I, LINE 2: EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. PART I, LINE 3: ACCRUAL BASIS PART III ACCOUNTING METHOD: PART II, LINE 1: ACCRUAL BASIS 1 ART CENTER COLLEGE OF DESIGN 1700 LIDA STREET PASADENA CA 91103 951921340 501(C)(3) 15675 0 RESEARCH SUBGRANT CAL POLY CORPORATION 1 GRAND AVE SAN LUIS OBISPO CA 93407 951648180 501(C)(3) 6945 0 RESEARCH SUBGRANT CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE NORD HALL CLEVELAND OH 441067037 341018992 501(C)(3) 243232 0 RESEARCH SUBGRANT COLORADO STATE UNIVERSITY 6015 CAMPUS DELIVERY FORT COLLINS CO 80523 846000545 GOVT 352416 0 RESEARCH SUBGRANT DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 132496 0 RESEARCH SUBGRANT GLOBAL ALGAE INNOVATIONS 486 LIVE OAK DRIVE EL CAJON CA 92020 455319556 275801 0 RESEARCH SUBGRANT LAWRENCE LIVERMORE NATIONAL LABORATORY 7000 EAST AVE LIVERMORE CA 94550 205624386 GOVT 105000 0 RESEARCH SUBGRANT LELAND STANFORD JR UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 30463 0 RESEARCH SUBGRANT NORTHWESTERN UNIVERSITY 633 CLARK ST G547 EVANSTON IL 60208 362167817 501(C)(3) 76964 0 RESEARCH SUBGRANT NOVA SOUTHEASTERN UNIVERSITY INC 3100 SW 9TH AVENUE FORT LAUDERDALE FL 33315 591083502 501(C)(3) 49636 0 RESEARCH SUBGRANT REGENTS UNIVERSITY OF MINNESOTA PO BOX 1450 NW 5957 MINNEAPOLIS MN 554855957 430653611 GOVT 156201 0 RESEARCH SUBGRANT RHODE ISLAND HOSPITAL 1 HOPPIN STREET BOX 42 SUITE 1300 PROVIDENCE RI 029034923 050258954 501(C)(3) 303650 0 RESEARCH SUBGRANT SANTA FE INSTITUTE 1399 HYDE PARK ROAD SANTA FE NM 875018943 850325494 501(C)(3) 98419 0 RESEARCH SUBGRANT TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVE BOSTON MA 02215 042103547 501(C)(3) 5642 0 RESEARCH SUBGRANT UNIVERSITY OF ALABAMA BIRMINGHAM 1720 2ND AVENUE SOUTH BIRMINGHAM AL 35294 636005396 GOVT 34829 0 RESEARCH SUBGRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DR LA JOLLA CA 92037 566001393 GOVT 687776 0 RESEARCH SUBGRANT UNIVERSITY OF MARYLAND 4300 TERRAPIN TRAIL COLLEGE PARK MD 20742 526002033 GOVT 26098 0 RESEARCH SUBGRANT VANDERBILT UNIVERSITY 2201 WEST END AVE NASHVILLE TN 37235 620476822 501(C)(3) 289736 0 RESEARCH SUBGRANT 17 1 PART I, LINE 2: EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. X 1 1 X X X X 0 0 0 0 0 0 0 0 0 VENTER JOHN CRAIG CHAIRMAN & CEO 1175385 0 0 0 15680 0 12200 0 5520 0 1208785 0 0 0 SCHEUERMANN RICHARD H DIRECTOR, LA JOLLA CAMPUS 347428 0 0 0 8372 0 12200 0 16236 0 384236 0 0 0 KOWALSKI HEATHER CHIEF OPERATING OFFICER 355385 0 0 0 5067 0 12200 0 6333 0 378985 0 0 0 MULLEN JILL SR. VP OF PHILANTHROPY 302088 0 0 0 7065 0 12200 0 17356 0 338709 0 0 0 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 292068 0 0 0 2551 0 11800 0 3642 0 310061 0 0 0 YUMUL MARY VP OF HUMAN RESOURCES 251951 0 0 0 2498 0 10400 0 21739 0 286588 0 0 0 STOUT MARTIN CHIEF TECHNOLOGY OFFICER 248878 0 0 0 8266 0 7985 0 20677 0 285806 0 0 0 STAYEAS TIMOTHY NETWORK TEAM LEAD 214831 0 0 0 1492 0 8996 0 19881 0 245200 0 0 0 FOUTS DERRICK PROFESSOR 199878 0 0 0 1872 0 8319 0 22129 0 232198 0 0 0 SINGH INDRESH SR. SOFTWARE ENGINEER 198802 0 0 0 1876 0 8355 0 19829 0 228862 0 0 0 ADELSON JULIE VP, LEG. AFFRS/GENERAL COUNSEL 177269 0 0 0 19952 0 7200 0 2033 0 206454 0 0 0 PART I, LINE 1A SCHEDULE J, PART I, LINE 1A: TAX INDEMIFICATION AND GROSS-UP PAYMENTS - CERTAIN AWARDS ARE GROSSED UP FOR INCOME TAX AND INCLUDED AS TAXABLE COMPENSATION. FORM 990, PART VI, SECTION A, LINE 2 BOARD MEMBERS HEATHER KOWALSKI AND J. CRAIG VENTER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY MANAGEMENT AND THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C JCVI MONITORS COMPLIANCE TO ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL SOLICITATION OF CONFLICT OF INTEREST STATEMENTS FROM TRUSTEES, OFFICERS, AND EMPLOYEES. IF A PERSON HAS A CONFLICT WITH RESPECT TO A TRANSACTION, SUCH PERSON IS NOT ALLOWED TO VOTE ON THAT TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 JCVI USES AN OUTSIDE COMPENSATION CONSULTANT TO PROVIDE A LIST OF COMPARABLE SALARIES FOR THE CEO AND OFFICERS THESE ARE REVIEWED BY THE JCVI COMPENSATION COMMITTEE AND CEO BEFORE A FINAL DETERMINATION IS MADE. THIS PROCESS WAS DOCUMENTED AND LAST DONE IN OCTOBER 2018. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: K-1 PASSTHROUGH -27,731. DONATED RENT 11,880,000.